Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Systems biology in drug discovery and development [[electronic resource] /] / edited by Daniel L. Young and Seth Michelson
| Systems biology in drug discovery and development [[electronic resource] /] / edited by Daniel L. Young and Seth Michelson |
| Pubbl/distr/stampa | Hoboken, New Jersey, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (398 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
YoungDaniel L
MichelsonSeth |
| Collana | Wiley Series on Technologies for the Pharmaceutical Industry |
| Soggetto topico |
Drug development
Systems biology |
| ISBN |
1-283-27369-1
9786613273697 1-118-01643-2 1-118-01642-4 1-118-01641-6 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
SYSTEMS BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; PART I: INTRODUCTION TO SYSTEMS BIOLOGY IN APPROACH; CHAPTER 1: Introduction to Systems Biology in Drug Discovery and Development; SYSTEMS BIOLOGY IN PHARMACOLOGY; REFERENCES; CHAPTER 2: Methods for In Silico Biology: Model Construction and Analysis; 2.1. INTRODUCTION; 2.2. MODEL BUILDING; 2.3. PARAMETER ESTIMATION; 2.4. MODEL ANALYSIS; 2.5. CONCLUSIONS; REFERENCES; CHAPTER 3: Methods in In Silico Biology: Modeling Feedback Dynamics in Pathways; 3.1. INTRODUCTION; 3.2. STATISTICAL MODELING
3.3. MATHEMATICAL MODELING3.4. FEEDBACK AND FEEDFORWARD; 3.5. CONCLUSIONS; REFERENCES; CHAPTER 4: Simulation of Population Variability in Pharmacokinetics; 4.1. INTRODUCTION; 4.2. PBPK MODELING; 4.3. SIMULATION OF PHARMACOKINETIC VARIABILITY; 4.4. CONCLUSIONS AND FUTURE DIRECTIONS; REFERENCES; PART II: APPLICATIONS TO DRUG DISCOVERY; CHAPTER 5: Applications of Systems Biology Approaches to Target Identification and Validation in Drug Discovery; 5.1. INTRODUCTION; 5.2. TYPICAL DRUG DISCOVERY PARADIGM; 5.3. INTEGRATED DRUG DISCOVERY 5.4. DRIVERS OF THE DISEASE PHENOTYPE: CLINICAL ENDPOINTS AND HYPOTHESES5.5. EXTRACELLULAR DISEASE DRIVERS: MECHANISTIC BIOTHERAPEUTIC MODELS; 5.6. RELEVANT CELL MODELS FOR CLINICAL ENDPOINTS; 5.7. INTRACELLULAR DISEASE DRIVERS: SIGNALING PATHWAY QUANTIFICATION; 5.8. TARGET SELECTION: DYNAMIC PATHWAY MODELING; 5.9. CONCLUSIONS; REFERENCES; CHAPTER 6: Lead Identification and Optimization; 6.1. INTRODUCTION; 6.2. THE SYSTEMS BIOLOGY TOOL KIT; 6.3. CONCLUSIONS; REFERENCES; CHAPTER 7: Role of Core Biological Motifs in Dose-Response Modeling: An Example with Switchlike Circuits 7.1. INTRODUCTION: SYSTEMS PERSPECTIVES IN DRUG DISCOVERY7.2. SYSTEMS BIOLOGY AND TOXICOLOGY; 7.3. MECHANISTIC AND COMPUTATIONAL CONCEPTS IN A MOLECULAR OR CELLULAR CONTEXT; 7.4. RESPONSE MOTIFS IN CELL SIGNALING AND THEIR ROLE IN DOSE RESPONSE; 7.5. DISCUSSION AND CONCLUSIONS; REFERENCES; CHAPTER 8: Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling During Discovery and Early Development; 8.1. INTRODUCTION; 8.2. CHALLENGES IN DRUG DISCOVERY AND DEVELOPMENT; 8.3. METHODOLOGICAL ASPECTS AND CONCEPTS; 8.4. USE OF PK-PD MODELS IN LEAD OPTIMIZATION 8.5. USE OF PK-PD MODELS IN CLINICAL CANDIDATE SELECTION8.6. ENTRY-INTO-HUMAN PREPARATION AND TRANSLATIONAL PK-PD MODELING; 8.7. USE OF PK-PD MODELS IN TOXICOLOGY STUDY DESIGN AND EVALUATION; 8.8. JUSTIFICATION OF STARTING DOSE, CALCULATION OF SAFETY MARGINS, AND SUPPORT OF PHASE I DESIGN; 8.9. PHASE I AND BEYOND; 8.10. SUPPORT OF EARLY FORMULATION DEVELOPMENT; 8.11. OUTLOOK AND CONCLUSIONS; REFERENCES; PART III: APPLICATIONS TO DRUG DEVELOPMENT; CHAPTER 9: Developing Oncology Drugs Using Virtual Patients of Vascular Tumor Diseases; 9.1. INTRODUCTION; 9.2. MODELING ANGIOGENESIS 9.3. USE OF RIGOROUS MATHEMATICAL ANALYSIS TO GAIN INSIGHT INTO DRUG DEVELOPMENT |
| Record Nr. | UNINA-9910139600603321 |
| Hoboken, New Jersey, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Systems biology in drug discovery and development / / edited by Daniel L. Young and Seth Michelson
| Systems biology in drug discovery and development / / edited by Daniel L. Young and Seth Michelson |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, New Jersey, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (398 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
YoungDaniel L
MichelsonSeth |
| Collana | Wiley Series on Technologies for the Pharmaceutical Industry |
| Soggetto topico |
Drug development
Systems biology |
| ISBN |
1-283-27369-1
9786613273697 1-118-01643-2 1-118-01642-4 1-118-01641-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
SYSTEMS BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; PART I: INTRODUCTION TO SYSTEMS BIOLOGY IN APPROACH; CHAPTER 1: Introduction to Systems Biology in Drug Discovery and Development; SYSTEMS BIOLOGY IN PHARMACOLOGY; REFERENCES; CHAPTER 2: Methods for In Silico Biology: Model Construction and Analysis; 2.1. INTRODUCTION; 2.2. MODEL BUILDING; 2.3. PARAMETER ESTIMATION; 2.4. MODEL ANALYSIS; 2.5. CONCLUSIONS; REFERENCES; CHAPTER 3: Methods in In Silico Biology: Modeling Feedback Dynamics in Pathways; 3.1. INTRODUCTION; 3.2. STATISTICAL MODELING
3.3. MATHEMATICAL MODELING3.4. FEEDBACK AND FEEDFORWARD; 3.5. CONCLUSIONS; REFERENCES; CHAPTER 4: Simulation of Population Variability in Pharmacokinetics; 4.1. INTRODUCTION; 4.2. PBPK MODELING; 4.3. SIMULATION OF PHARMACOKINETIC VARIABILITY; 4.4. CONCLUSIONS AND FUTURE DIRECTIONS; REFERENCES; PART II: APPLICATIONS TO DRUG DISCOVERY; CHAPTER 5: Applications of Systems Biology Approaches to Target Identification and Validation in Drug Discovery; 5.1. INTRODUCTION; 5.2. TYPICAL DRUG DISCOVERY PARADIGM; 5.3. INTEGRATED DRUG DISCOVERY 5.4. DRIVERS OF THE DISEASE PHENOTYPE: CLINICAL ENDPOINTS AND HYPOTHESES5.5. EXTRACELLULAR DISEASE DRIVERS: MECHANISTIC BIOTHERAPEUTIC MODELS; 5.6. RELEVANT CELL MODELS FOR CLINICAL ENDPOINTS; 5.7. INTRACELLULAR DISEASE DRIVERS: SIGNALING PATHWAY QUANTIFICATION; 5.8. TARGET SELECTION: DYNAMIC PATHWAY MODELING; 5.9. CONCLUSIONS; REFERENCES; CHAPTER 6: Lead Identification and Optimization; 6.1. INTRODUCTION; 6.2. THE SYSTEMS BIOLOGY TOOL KIT; 6.3. CONCLUSIONS; REFERENCES; CHAPTER 7: Role of Core Biological Motifs in Dose-Response Modeling: An Example with Switchlike Circuits 7.1. INTRODUCTION: SYSTEMS PERSPECTIVES IN DRUG DISCOVERY7.2. SYSTEMS BIOLOGY AND TOXICOLOGY; 7.3. MECHANISTIC AND COMPUTATIONAL CONCEPTS IN A MOLECULAR OR CELLULAR CONTEXT; 7.4. RESPONSE MOTIFS IN CELL SIGNALING AND THEIR ROLE IN DOSE RESPONSE; 7.5. DISCUSSION AND CONCLUSIONS; REFERENCES; CHAPTER 8: Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling During Discovery and Early Development; 8.1. INTRODUCTION; 8.2. CHALLENGES IN DRUG DISCOVERY AND DEVELOPMENT; 8.3. METHODOLOGICAL ASPECTS AND CONCEPTS; 8.4. USE OF PK-PD MODELS IN LEAD OPTIMIZATION 8.5. USE OF PK-PD MODELS IN CLINICAL CANDIDATE SELECTION8.6. ENTRY-INTO-HUMAN PREPARATION AND TRANSLATIONAL PK-PD MODELING; 8.7. USE OF PK-PD MODELS IN TOXICOLOGY STUDY DESIGN AND EVALUATION; 8.8. JUSTIFICATION OF STARTING DOSE, CALCULATION OF SAFETY MARGINS, AND SUPPORT OF PHASE I DESIGN; 8.9. PHASE I AND BEYOND; 8.10. SUPPORT OF EARLY FORMULATION DEVELOPMENT; 8.11. OUTLOOK AND CONCLUSIONS; REFERENCES; PART III: APPLICATIONS TO DRUG DEVELOPMENT; CHAPTER 9: Developing Oncology Drugs Using Virtual Patients of Vascular Tumor Diseases; 9.1. INTRODUCTION; 9.2. MODELING ANGIOGENESIS 9.3. USE OF RIGOROUS MATHEMATICAL ANALYSIS TO GAIN INSIGHT INTO DRUG DEVELOPMENT |
| Record Nr. | UNINA-9910821853303321 |
| Hoboken, New Jersey, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||